Confusion, a rather serious adverse drug reaction with valproic acid: A review of the french pharmacovigilance database

Pharmacopsychiatry

Volumn 42, Issue 2, 2009, Pages 61-65

  Bondon Guitton, E ^a   Sommet, A ^a,b   Montastruc, J L ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACEPROMAZINE; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CARBAMAZEPINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLORAZEPATE; ETHOSUXIMIDE; ETIRACETAM; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MEMANTINE; MIANSERIN; OPIATE; PHENOBARBITAL; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIOXANTHENE DERIVATIVE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VIGABATRIN; VILOXAZINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGITATION; AKINESIA; AMNESIA; APATHY; APNEA; APRAXIA; ARTICLE; ASTHENIA; ATAXIA; BALANCE IMPAIRMENT; BLINDNESS; BRADYPNEA; CHILD; COMA; COMBINATION CHEMOTHERAPY; CONFUSION; CONVULSION; DATA BASE; DIPLOPIA; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; DYSKINESIA; DYSURIA; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FEMALE; FEVER; FLAPPING TREMOR; FRANCE; HALLUCINATION; HEADACHE; HEMIPARESIS; HEPATITIS; HUMAN; HYPERAMMONEMIA; HYPERESTHESIA; HYPONATREMIA; INFANT; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MYDRIASIS; MYOCLONUS; NAUSEA; NYSTAGMUS; OUTCOME ASSESSMENT; PARESTHESIA; PERSONALITY DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STUPOR; THROMBOCYTOPENIA; TREMOR; URINE INCONTINENCE; VOMITING; AGE; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; HOSPITALIZATION; MIDDLE AGED; MORTALITY; TIME;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CONFUSION; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INFANT; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 67649216587     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1102912     Document Type: Article

References (26)

1. Alvarez-Gomez M, Vaamonde J, Narbona J et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993 ; 16 : 451-455
2. Armon C, Shin C, Miller P et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996 ; 47 : 626-635
3. Begaud B, Evreux J, Jouglard J et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985 ; 40 : 111-118
4. Begaud B, Martin K, Haramburu F et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002 ; 288 : 1588
5. Belton K. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997 ; 52 : 423-427
6. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995 ; 122 : 422-429
7. Cenraud B, Pautrizel B, Berets O et al. Severe vigilance disturbances: a rare complication of sodium valproate treatment. Rev Electroencephalogr Neurophysiol Clin 1980 ; 10 : 376
8. Dubois B. Mental Confusion. In: Godeau P, Herson S, Piette JC, ed. Trait é de M é decine Interne 4 è me é dition. Paris: M é decine Sciences Flammarion ; 2004 ; 2441-2443
9. Durán-Ferreras E, Jim é nez-Vilches PL, Galá-Barranco JM et al. Hyperammonaemic encephalopathy due to valproic acid. Rev Neurol 2008 ; 46 : 537-539
10. Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000 ; 356 : 1255-1559
11. Ellaway C, Bennetts B, Tuck R et al. Clumsiness, confusion, coma, and valproate. Lancet 1999 ; 535 : 1408
12. Gomceli YB, Kutlu G, Cavdar L et al. Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav 2007 ; 10 : 583-587
13. International Conference on Harmonisation. Guidance on addendum to E2C clinical safety data management: periodic safety update reports for marketed drugs. Fed Regist 2004 ; 69 : 5551-5552
14. Larrieu J, Lagueny A, Julien J. State of confusion induced by valproic acid and reversed after administration of clonazepam. Rev Electroencephalogr Neurophysiol Clin 1985 ; 15 : 179-184
15. Marescaux C, Warter J, Micheletti G et al. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982 ; 23 : 297-305
16. Masmoudi K, Gras-Champel V, Masson H et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006 ; 39 : 9-12
17. MacCormick WC, Kukull WA, Belle G van et al. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc 1994 ; 42 : 517-522
18. Montastruc JL, Sommet A, Lacroix I et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006 ; 73 : 629-632
19. Onder G, Gambassi G, Scales C et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 2002 ; 58 : 371-377 (Pubitemid 34983929)
20. Owens MJ, NemeroffCB. Pharmacology of valproate. Psychopharmacol Bull 2003 ; 37 : 17-24
21. Segura-Bruna N, Rodriguez-Campello A, Puente V et al. Valproateinduced hyperammonemic encephalopathy. Acta Neurol Scand 2006 ; 114 : 1-7
22. Stephens J, Levy R. Effects of valproate and citrulline on ammoniuminduced encephalopathy. Epilepsia 1994 ; 35 : 164-171
23. Thiessard F, Roux E, Miremont-Salame G et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986 - 2001). Drug Saf 2005 ; 28 : 731-740
24. Uthamalingam S, Kumar S, Vasudevan A et al. Drowsiness and disorientation in a woman with depression. J Am Geriatr Soc 2005 ; 53 : 1638-9163
25. Valproate. In: Sean C Sweetman, eds. Martindale. The Complete Drug Reference. 35th edition. London: Pharmaceutical Press ; 2007 ; 458-462
26. WHO Collaborating Centre for International Drug Monitoring. International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala: WHO ; 1992